Secondary outcome measures
BPD, patent ductus arteriosus

Group comparison of proportion of “early” (before 3 h of life as defined by Raschetti [Need of MV in the first 3 days of life.FiOSpOProportion of infants needing surfactant treatment.Duration of non-invasive and invasive respiratory support.Proportion of infants who need multiple doses of surfactant.Pharmacological and/or surgical treatment of patent ductus arteriosus (PDA).Pneumothorax (PNX) rate.Length of stay in hospital.BPD rate (using multiple definition) and severity.Mortality rate.